Phase 2 Hepatitis B Trial, Recruiting NCT06887036 Sponsor: Fondazione Epatocentro Ticino Condition: Hepatitis B
Back to Hepatitis B

Phase 2 Hepatitis B Trial, Recruiting

NCT06887036
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have given their signed agreement to take part in the study
  • People aged 18 or older but under 80 years old
  • People who have a confirmed long-term (chronic) Hepatitis B virus (HBV) infection, sometimes called being an "inactive HBV carrier"
  • People whose Hepatitis B surface antigen (HBsAg) blood levels fall within a specific range (20–15,000 IU/ml), measured on at least two separate occasions between 6 and 18 months apart
  • People whose Hepatitis B virus DNA levels fall within a specific range (1,000–20,000 IU/ml), measured on at least two separate occasions between 6 and 18 months apart
  • Women who could become pregnant must have a negative pregnancy test before joining

Who may not be able to join:

  • People who have refused to take part in the study
  • People with a known condition called G-6-Phosphatase deficiency (a specific inherited enzyme disorder)
  • People currently taking a type of medication that affects serotonin levels in the body (confirm with trial site for specific medications)
  • People currently being treated with antiviral medications for Hepatitis B known as nucleoside or nucleotide analogues
  • People who have another significant liver condition alongside their Hepatitis B
  • People whose liver enzyme levels (GPT) are more than twice the normal upper limit
  • People whose liver stiffness scan (Fibroscan) result was above 8.0 kPa within the 12 months before the study screening visit
  • People who test positive for a specific Hepatitis B marker called HBeAg
  • People who test positive for antibodies to a related virus called Hepatitis D (HDV)
  • Women who are currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 0041 91 910 6570

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Fondazione Epatocentro Ticino
Registry
ClinicalTrials.gov
Start date
1 September 2025
Est. completion
31 October 2026

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Reduction >1 log10 in the starting HBsAg level and > 2 log10 in the starting HBV DNA PCR level

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov